NCT05439499 2022-07-06This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.Ahon Pharmaceutical Co., Ltd.Phase 3 Unknown434 enrolled
NCT03966898 2021-06-02A Study of SHR6390 in Combination With Letrozole or Anastrozole in Patients With HR Positive and HER2 Negative Advanced Breast CancerJiangsu HengRui Medicine Co., Ltd.Phase 3 Unknown426 enrolled
NCT00327769 2011-01-25Faslodex Advanced Breast Cancer Local Chinese StudyAstraZenecaPhase 3 Completed234 enrolled